Endonovo Therapeutics Provides SofPulse® To All NFL Teams [Updated]

About this update from Endonovo Therapeutics, Inc.

[{"type":"text","content":"\n Los Angeles, CA, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDVD) (\"Endonovo\" or the \"Company\"), announced today the delivery of SofPulse® evaluation units to all thirty-two National Football League (“NFL”) teams. Alan Collier, CEO of Endonovo Therapeutics stated, “With injuries affecting the NFL more than any other professional sports league, we are pleased to support the health of NFL players by providing SofPulse® evaluation units to all NFL teams. The SofPulse® device is clinically proven to reduce post-operative pain, swelling and need for opioids. Endonovo is committed to helping NFL players get back on the field faster when recovering from medical procedures caused by injuries. We are currently expanding our sales and marketing efforts to other leagues and all levels, from high school to professional athletes.” Dr. Nev Zubcevik, Harvard trained Physical Medicine and Rehabilitation specialist with years of experience serving professional athletes, and Chief Medical Officer of Endonovo Therapeutics said, “The microcurrents in SofPulse® reduce swelling and speed up the natural recovery process. The SofPulse® technology treats swelling and reduces inflammation by improving blood flow. We believe that injured NFL players undergoing medical procedures will benefit greatly from the SofPulse® technology.” About Endonovo Therapeutics Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals® therapeutic devices. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals® therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome and multiple sclerosis. The Company's non-invasive Electroceutical® therapeutic device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company's current portfolio of pre-clinical stage Electroceuticals&#174...

More updates from Endonovo Therapeutics, Inc.